UA102258C2 - Pharmaceutical combination - Google Patents

Pharmaceutical combination

Info

Publication number
UA102258C2
UA102258C2 UAA201100102A UAA201100102A UA102258C2 UA 102258 C2 UA102258 C2 UA 102258C2 UA A201100102 A UAA201100102 A UA A201100102A UA A201100102 A UAA201100102 A UA A201100102A UA 102258 C2 UA102258 C2 UA 102258C2
Authority
UA
Ukraine
Prior art keywords
involve
pharmaceutical combination
treatment
diseases
relates
Prior art date
Application number
UAA201100102A
Other languages
English (en)
Ukrainian (uk)
Inventor
Мартин Фридрих Штефаник
Франк Хильберг
Рольф Кайзер
Девид Шапиро
Original Assignee
Берингер Ингельхайм Интернациональ Гмбх
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40912046&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA102258(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Берингер Ингельхайм Интернациональ Гмбх filed Critical Берингер Ингельхайм Интернациональ Гмбх
Publication of UA102258C2 publication Critical patent/UA102258C2/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Pathology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Reproductive Health (AREA)
  • Emergency Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)

Abstract

В заявке описана фармацевтическая комбинация; которая включает 3-Z-[1-(4-(N-((4-метилпиперизин-1-ил)метилкарбонил)-N-метиламино)анилино)-1-фенилметилен]-6-метоксикарбонил-2-индолинон или ее фармацевтически приемлемую соль и N-[4-[2-(2-амино-4,7-дигидро-4-оксо-1Н-пирроло[2,3-d]пиримидин-5-ил)этил]бензоил]-L-глутаминовую кислоту или ее фармацевтически приемлемую соль, которую можно использовать для лечения заболеваний, которые включают пролиферацию клеток, миграцию или апоптоз миеломных клеток, ангиогенез или фиброз.
UAA201100102A 2008-06-06 2009-06-04 Pharmaceutical combination UA102258C2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08157749 2008-06-06
PCT/EP2009/056891 WO2009147218A1 (en) 2008-06-06 2009-06-04 Pharmaceutical combination

Publications (1)

Publication Number Publication Date
UA102258C2 true UA102258C2 (en) 2013-06-25

Family

ID=40912046

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201100102A UA102258C2 (en) 2008-06-06 2009-06-04 Pharmaceutical combination

Country Status (34)

Country Link
US (5) US20110178099A1 (ru)
EP (2) EP2985025B1 (ru)
JP (2) JP5993573B2 (ru)
KR (1) KR101760657B1 (ru)
CN (1) CN102056609B (ru)
AR (1) AR072061A1 (ru)
AU (1) AU2009254554B2 (ru)
CA (1) CA2726644C (ru)
CO (1) CO6280488A2 (ru)
CY (2) CY1116877T1 (ru)
DK (2) DK2985025T3 (ru)
EA (1) EA020046B1 (ru)
EC (1) ECSP10010716A (ru)
ES (2) ES2662824T3 (ru)
HK (1) HK1152640A1 (ru)
HR (2) HRP20151186T1 (ru)
HU (2) HUE037291T2 (ru)
IL (1) IL208953B (ru)
LT (1) LT2985025T (ru)
MA (1) MA32384B1 (ru)
ME (1) ME02273B (ru)
MX (1) MX338047B (ru)
MY (1) MY158929A (ru)
NZ (1) NZ588957A (ru)
PE (1) PE20100084A1 (ru)
PL (2) PL2293795T3 (ru)
PT (2) PT2293795E (ru)
RS (2) RS57035B1 (ru)
SI (2) SI2985025T1 (ru)
TW (1) TWI447113B (ru)
UA (1) UA102258C2 (ru)
UY (1) UY31866A (ru)
WO (1) WO2009147218A1 (ru)
ZA (1) ZA201007594B (ru)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050043233A1 (en) 2003-04-29 2005-02-24 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis
PE20060777A1 (es) 2004-12-24 2006-10-06 Boehringer Ingelheim Int Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas
UA107560C2 (uk) * 2008-06-06 2015-01-26 Фармацевтична лікарська форма для негайного вивільнення похідної індолінону
KR20170020557A (ko) * 2008-06-06 2017-02-22 베링거 인겔하임 인터내셔날 게엠베하 인돌리논 유도체의 현탁 제형을 포함하는 캡슐 약제학적 투여 형태
US20170065529A1 (en) 2015-09-09 2017-03-09 Boehringer Ingelheim International Gmbh Pharmaceutical dosage form for immediate release of an indolinone derivative
US20140350022A1 (en) 2013-05-10 2014-11-27 Boehringer Ingelheim International Gmbh Efficacious treatment of NSCLC and predictive clinical marker of the responsiveness of a tumour to a treatment
JP6799201B2 (ja) 2013-07-31 2020-12-16 アヴァリン ファーマ インク． エアロゾルチロシンキナーゼ阻害剤の化合物、及びその使用
ES2775179T3 (es) * 2015-10-21 2020-07-24 Capsugel Belgium Nv Proceso de impresión para formas de dosificación orales

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL96531A (en) 1989-12-11 1995-08-31 Univ Princeton History of Acid N- (Diomeric-H1-Pyrolo] D-2,3 [Pyrimidine-3-Ilacyl (-glutamic, preparation and pharmaceutical preparations containing them)
WO2005070469A1 (en) * 2004-01-23 2005-08-04 Sarissa, Inc. Methods of treating mesothelioma using an antisense oligonucleotide to thymidylate synthase
AU6890800A (en) * 1999-08-23 2001-03-19 Eli Lilly And Company A novel crystalline form of disodium n-[4-[2-(2-amino-4,7-dihydro-4-oxo-3h-pyrrolo[2,3-D]- pyrimidin-5-yl)ethyl]benzoyl]-l-glutamic acid salt and processes therefor
UA75054C2 (ru) 1999-10-13 2006-03-15 Бьорінгер Інгельхайм Фарма Гмбх & Ко. Кг Замещенные в положении 6 индолиноны, их получение и их применение как лекарственного средства
DE10233500A1 (de) * 2002-07-24 2004-02-19 Boehringer Ingelheim Pharma Gmbh & Co. Kg 3-Z-[1-(4-(N-((4-Methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylen]-6-methoxycarbonyl-2-indolinon-Monoethansulfonat und dessen Verwendung als Arzneimittel
US20040204458A1 (en) * 2002-08-16 2004-10-14 Boehringer Ingelheim Pharma Gmbh & Co. Kg Use of Lck inhibitors for treatment of immunologic diseases
DE10237423A1 (de) 2002-08-16 2004-02-19 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung von LCK-Inhibitoren für die Behandlung von immunologischen Erkrankungen
US7148249B2 (en) * 2002-09-12 2006-12-12 Boehringer Ingelheim Pharma Gmbh & Co. Kg Indolinones substituted by heterocycles, the preparation thereof and their use as medicaments
US20050043233A1 (en) 2003-04-29 2005-02-24 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis
US20060058311A1 (en) * 2004-08-14 2006-03-16 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation
WO2006023010A1 (en) * 2004-08-18 2006-03-02 Salmedix, Inc. Alanosine formulations and methods of use
PE20060777A1 (es) * 2004-12-24 2006-10-06 Boehringer Ingelheim Int Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas
WO2007057397A1 (en) * 2005-11-15 2007-05-24 Boehringer Ingelheim International Gmbh Treatment of cancer
EP1870400A1 (en) 2006-06-08 2007-12-26 Boehringer Ingelheim Pharma GmbH & Co. KG Salts and crystalline salt forms of an 2-indolinone derivative
WO2008021410A2 (en) * 2006-08-14 2008-02-21 Sicor Inc. Highly pure pemetrexed diacid and processes for the preparation thereof

Also Published As

Publication number Publication date
MX2010012937A (es) 2011-02-25
HK1152640A1 (en) 2012-03-09
EA201001853A1 (ru) 2011-06-30
AR072061A1 (es) 2010-08-04
EP2985025B1 (en) 2018-01-17
PE20100084A1 (es) 2010-02-05
US20160250218A1 (en) 2016-09-01
AU2009254554A1 (en) 2009-12-10
US20110178099A1 (en) 2011-07-21
NZ588957A (en) 2013-03-28
HRP20151186T1 (hr) 2015-12-04
EP2293795B1 (en) 2015-08-12
US20130237549A1 (en) 2013-09-12
CO6280488A2 (es) 2011-05-20
MY158929A (en) 2016-11-30
ME02273B (me) 2016-02-20
KR20110025172A (ko) 2011-03-09
CA2726644C (en) 2018-02-06
ZA201007594B (en) 2011-07-27
HRP20180602T1 (hr) 2018-05-18
EP2985025A1 (en) 2016-02-17
UY31866A (es) 2010-01-29
EP2293795A1 (en) 2011-03-16
LT2985025T (lt) 2018-04-10
SI2293795T1 (sl) 2015-12-31
HUE025821T2 (en) 2016-04-28
JP5993573B2 (ja) 2016-09-14
HUE037291T2 (hu) 2018-08-28
KR101760657B1 (ko) 2017-07-24
JP2015007143A (ja) 2015-01-15
IL208953A0 (en) 2011-01-31
CN102056609B (zh) 2012-12-05
US20150174126A1 (en) 2015-06-25
PL2293795T3 (pl) 2016-01-29
TW201002690A (en) 2010-01-16
JP2011522008A (ja) 2011-07-28
ES2662824T3 (es) 2018-04-09
DK2985025T3 (en) 2018-03-19
TWI447113B (zh) 2014-08-01
CA2726644A1 (en) 2009-12-10
RS54293B1 (en) 2016-02-29
PT2293795E (pt) 2015-11-17
SI2985025T1 (en) 2018-04-30
EA020046B1 (ru) 2014-08-29
ECSP10010716A (es) 2011-02-28
ES2552238T3 (es) 2015-11-26
WO2009147218A1 (en) 2009-12-10
CY1116877T1 (el) 2017-04-05
CN102056609A (zh) 2011-05-11
RS57035B1 (sr) 2018-05-31
MA32384B1 (fr) 2011-06-01
MX338047B (es) 2016-03-31
AU2009254554B2 (en) 2015-08-20
PL2985025T3 (pl) 2018-06-29
PT2985025T (pt) 2018-03-15
DK2293795T3 (en) 2015-10-19
CY1120505T1 (el) 2019-07-10
IL208953B (en) 2018-03-29
US20180243308A1 (en) 2018-08-30

Similar Documents

Publication Publication Date Title
MXPA05011656A (es) Combinaciones para el tratamiento de enfermedades que implican proliferacion, migracion o apoptosis celulares de celulas de mieloma, o angiogenesis.
MX338047B (es) Combinacion farmaceutica útil para el tratamiento fr enfermedades que involucran proliferación celular, migración o apoptosis de células de mieloma, angiogéneisis o fibrosis.
AU2011328009A8 (en) Compounds and methods for treating pain
BR112012023021A2 (pt) compostos de indazol e seus usos
WO2015095819A3 (en) Cancer treatment using combinations of erk and raf inhibitors
MY166014A (en) Combination therapy methods for treating proliferative diseases
MY183661A (en) Treatment of cancer with tor kinase inhibitors
UA86586C2 (ru) Комбинация для лечения заболеваний, связанных с клеточной пролиферацией, миграцией или апоптозом клеток миеломы или с ангиогенезом
MY175979A (en) Certain chemical entities, compositions and methods
NZ700881A (en) Compositions and methods comprising celecoxib or related compounds and dextromethorphan
NZ726488A (en) Compositions and methods for transmucosal absorption
MX2015001122A (es) Combinaciones farmaceuticas de un inhibidor de cdk4/6 y un inhibidor de b-raf.
GB201318761D0 (en) Compounds for the treatment of neuropsychiatric disorders
GB201111485D0 (en) Drug composition and its use in therapy
WO2012159085A3 (en) Compositions and methods for treating and preventing cancer by targeting and inhibiting cancer stem cells
WO2009129531A3 (en) Bupivacaine formulation in a polyorthoester carrier
WO2008030538A3 (en) Cancer stem cell-targeted cancer therapy
WO2014160216A3 (en) Dual targeting anticancer agents
WO2009129527A3 (en) Baclofen formulation in a polyorthoester carrier
MX2013006319A (es) Composiciones y metodos para tratar el cancer usando un inhibidor de pi3k y un inhibidor de mek.
UA106353C2 (en) Carbamoyl derivatives of bicyclic carbonylamino-pyrazoles as prodrugs
MX2018004112A (es) Terapia de combinacion racional para el tratamiento de cancer.
TN2010000556A1 (en) Pharmaceutical combination
TN2014000418A1 (en) Methods for treating cancer using pi3k inhibitor and mek inhibitor
GB2527477A (en) Tumour Therapy